ICCC Q1 2021 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-16.4% YoY

Gross Profit

$2M39.0% margin

Operating Income

-$374,625-9.1% margin

Net Income

-$441,303-10.7% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+9.7%

Cash Flow

Operating Cash Flow

-$623,546

Free Cash Flow

-$972,862

Stock-Based Comp.

$34,629

Balance Sheet

Total Assets

$40M

Total Liabilities

$12M

Stockholders' Equity

$28M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-16.4%
Gross Profit	$2M	$2M	-28.3%
Operating Income	-$374,625	$196,877	-290.3%
Net Income	-$441,303	-$122,267	-260.9%